NECLIFE Stock Overview
Manufactures and sells pharmaceutical products in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Nectar Lifesciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹35.26 |
| 52 Week High | ₹56.50 |
| 52 Week Low | ₹25.40 |
| Beta | 1.03 |
| 11 Month Change | -5.42% |
| 3 Month Change | 9.20% |
| 1 Year Change | 37.73% |
| 33 Year Change | 44.51% |
| 5 Year Change | 163.13% |
| Change since IPO | 35.56% |
Recent News & Updates
Recent updates
Revenues Working Against Nectar Lifesciences Limited's (NSE:NECLIFE) Share Price Following 26% Dive
Oct 11
Nectar Lifesciences Limited (NSE:NECLIFE) Shares Fly 31% But Investors Aren't Buying For Growth
Aug 22Here's Why Nectar Lifesciences (NSE:NECLIFE) Has A Meaningful Debt Burden
Jul 27Nectar Lifesciences Limited (NSE:NECLIFE) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Feb 19Does Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?
Dec 22Nectar Lifesciences (NSE:NECLIFE) Has Debt But No Earnings; Should You Worry?
Jun 16Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt
Jun 21Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt
Jul 29Is Nectar Lifesciences Limited (NSE:NECLIFE) A Risky Dividend Stock?
Feb 25Nectar Lifesciences (NSE:NECLIFE) Has A Somewhat Strained Balance Sheet
Jan 21Zooming in on NSE:NECLIFE's 0.3% Dividend Yield
Nov 02Does Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?
Sep 07
If You Had Bought Nectar Lifesciences (NSE:NECLIFE) Stock A Year Ago, You Could Pocket A 47% Gain Today
Aug 09The Nectar Lifesciences (NSE:NECLIFE) Share Price Has Gained 47% And Shareholders Are Hoping For More
Aug 09What You Can Learn From Nectar Lifesciences Limited's (NSE:NECLIFE) P/E
Jul 13Shareholder Returns
| NECLIFE | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -3.6% | -3.2% | -3.4% |
| 1Y | 37.7% | 42.8% | 27.4% |
Return vs Industry: NECLIFE underperformed the Indian Pharmaceuticals industry which returned 42.8% over the past year.
Return vs Market: NECLIFE exceeded the Indian Market which returned 27.4% over the past year.
Price Volatility
| NECLIFE volatility | |
|---|---|
| NECLIFE Average Weekly Movement | 9.8% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: NECLIFE's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: NECLIFE's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 1,686 | Amit Chadah | www.neclife.com |
Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company’s active pharmaceutical ingredients and intermediates comprise cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins.
Nectar Lifesciences Limited Fundamentals Summary
| NECLIFE fundamental statistics | |
|---|---|
| Market cap | ₹7.91b |
| Earnings (TTM) | ₹61.44m |
| Revenue (TTM) | ₹16.49b |
128.7x
P/E Ratio0.5x
P/S RatioIs NECLIFE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NECLIFE income statement (TTM) | |
|---|---|
| Revenue | ₹16.49b |
| Cost of Revenue | ₹11.60b |
| Gross Profit | ₹4.89b |
| Other Expenses | ₹4.83b |
| Earnings | ₹61.44m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.27 |
| Gross Margin | 29.64% |
| Net Profit Margin | 0.37% |
| Debt/Equity Ratio | 59.4% |
How did NECLIFE perform over the long term?
See historical performance and comparison